Table 2 Local dose constraints for PTV, bladder and rectum and the number of plans meeting these constraints
From: Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses
Local dose constraint | Number of plans meeting constraint | ||
|---|---|---|---|
Control group | Prostheses group (IMRT clinical plan) | Prostheses group (VMAT replan) | |
PTV V95% > 98% | 50 (100%) | 16 (94%) | 17 (100%) |
PTV V105% < 2% | 50 (100%) | 17 (100%) | 17 (100%) |
Rectum V42Gy < 60% | 49 (98%) | 10 (59%) | 16 (94%) |
Rectum V50Gy < 50% | 49 (98%) | 14 (82%) | 16 (94%) |
Rectum V54Gy < 30% | 49 (98%) | 13 (76%) | 16 (94%) |
Rectum V58Gy < 15% | 46 (92%) | 16 (94%) | 16 (94%) |
Bladder V42Gy < 55% | 43 (86%) | 10 (59%) | 14 (82%) |
Bladder V50Gy < 40% | 40 (80%) | 9 (53%) | 14 (82%) |
Bladder V62Gy < 5% | 41 (82%) | 11 (65%) | 14 (82%) |